Holen Sie sich die Stockscreener-App
70.70
0.31%
-0.22
Handel nachbörslich:
67.00
-3.70
-5.23%
Schlusskurs vom Vortag:
$70.92
Offen:
$71.19
24-Stunden-Volumen:
846.06K
Relative Volume:
0.55
Marktkapitalisierung:
$5.68B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-11.90
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
-2.29%
1M Leistung:
-8.88%
6M Leistung:
+56.17%
1J Leistung:
+44.49%
1-Tages-Spanne:
$69.96
$71.92
1-Wochen-Bereich:
$69.75
$75.00
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
70.70 | 5.69B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics Withdraws Translarna NDA After FDA Feedback - TipRanks
PTC Therapeutics falls after withdrawing muscle disorder drug marketing application - TradingView
PTC Therapeutics stock falls after withdrawing Translarna drug application By Investing.com - Investing.com Canada
FDA skepticism ends PTC bid to market Duchenne drug Translarna in U.S. - Stock Titan
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
PTC Therapeutics (NASDAQ:PTCT) Shareholders Have Earned a 18% CAGR Over the Last Three Years - 富途牛牛
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU - MSN
Price Action: How does Guardian Pharmacy Services Inc correlate with NasdaqTrade Risk Assessment & Safe Entry Point Alerts - baoquankhu1.vn
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation - ChartMill
PTC Therapeutics, Inc. $PTCT Stock Position Decreased by BI Asset Management Fondsmaeglerselskab A S - MarketBeat
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026 - Finviz
Between PTC Therapeutics and Eli Lilly, Which Stock Looks Set to Break Out? - Trefis
PTC Therapeutics vs Merck: Which Is the Stronger Buy Today? - Trefis
Understanding Momentum Shifts in (PTCT) - Stock Traders Daily
Tech Rally: Is PTC Therapeutics Inc a stock for growth or value investorsJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
WCM Investment Management LLC Acquires Shares of 147,065 PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (PTCT) Investor Outlook: An 18% Upside Potential Amidst Robust Pipeline - DirectorsTalk Interviews
PTCT SEC FilingsPtc Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup - Chartmill
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Meme Stocks: What is PTC Therapeutics Inc.’s book value per shareEarnings Overview Summary & Growth Focused Entry Reports - baoquankhu1.vn
Evaluating PTC Therapeutics (PTCT) Valuation After Barclays Rating Upgrade And Growing Analyst Confidence - Yahoo Finance
Converging Analyst Upgrades on PTC’s Rare Disease Pipeline Might Change The Case For Investing In PTC Therapeutics (PTCT) - Sahm
Barclays Upgrades PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (PTCT) Sees Analyst Rating Upgrade to Overweigh - GuruFocus
PTC Therapeutics stock initiated with Overweight rating at Barclays By Investing.com - Investing.com Canada
PTC Therapeutics, Inc. (PTCT) Stock Analysis: Potential Upside with Innovative Rare Disorder Treatments - DirectorsTalk Interviews
A Look At PTC Therapeutics (PTCT) Valuation After New 2026 Revenue Guidance And Morgan Stanley Support - Sahm
Sector Gamma AS Increases Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Avoiding Lag: Real-Time Signals in (PTCT) Movement - Stock Traders Daily
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves - Finviz
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Momentum Shift: What is International Money Express Incs market positionTrade Exit Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
First Week of September 18th Options Trading For PTC Therapeutics - Nasdaq
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)? - Sahm
Discipline and Rules-Based Execution in PTCT Response - Stock Traders Daily
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics reports $92.5M in Q4 Sephience revenue By Investing.com - Investing.com Nigeria
Lobbying Update: $50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Ptc Therapeutics CEO Klein sells $192k in shares By Investing.com - Investing.com Nigeria
Ptc Therapeutics CEO Klein sells $192k in shares - Investing.com
Utter, SVP at Ptc Therapeutics, sells $79k in shares By Investing.com - Investing.com Canada
Pauwels Eric, chief business officer of Ptc Therapeutics, sells $566k in shares - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 4,602 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 881 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 866 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Sells $192,195.30 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 6.7%Here's Why - MarketBeat
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ptc Therapeutics Inc-Aktie (PTCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 08 '26 |
Sale |
76.50 |
4,602 |
352,057 |
82,887 |
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 09 '26 |
Sale |
77.41 |
1,722 |
133,300 |
81,165 |
| Pauwels Eric | CHIEF BUSINESS OFFICER |
Jan 12 '26 |
Sale |
78.70 |
1,024 |
80,589 |
80,141 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER |
Jan 08 '26 |
Sale |
76.45 |
2,514 |
192,195 |
394,453 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER |
Jan 08 '26 |
Sale |
76.45 |
866 |
66,206 |
92,428 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 08 '26 |
Sale |
76.56 |
4,033 |
308,760 |
113,626 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Jan 09 '26 |
Sale |
77.93 |
2,314 |
180,320 |
111,312 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 08 '26 |
Sale |
76.45 |
881 |
67,352 |
115,196 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER |
Jan 08 '26 |
Sale |
76.45 |
59 |
4,511 |
6,791 |
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):